{"transactions":[{"id":697766,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26798,"kind":"organization","name":"Black Robe Capital LLC","position":1,"cik":"0001977553","reported_name":"Black Robe Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26799,"kind":"person","name":"MCNULTY JAMES A","position":2,"cik":"0001275857","reported_name":"MCNULTY JAMES A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-05T01:03:05.000Z","date":"2026-07-01","kind":"gift","planned":false,"acquired":false,"shares":3200000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":19901057,"source":{"system":"sec-edgar","filing":"0001493152-26-036080","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315226036080/ownership.xml","form_type":"4"}},{"id":697765,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26796,"kind":"person","name":"OSMAN RONALD E","position":1,"cik":"0001380466","reported_name":"OSMAN RONALD E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26797,"kind":"organization","name":"Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012","position":2,"cik":"0001972372","reported_name":"Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-04T17:33:26.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan, subject to shareholder approval."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares represent 100,000 shares owned by Mr. Osman and remaining number of shares of common stock held by The Ronald E. Osman Trust III. Mr. Osman is the sole trustee of the Ronald E. Osman Trust III."}],"balance_after":23614985,"source":{"system":"sec-edgar","filing":"0001493152-26-035962","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315226035962/ownership.xml","form_type":"4"}},{"id":697764,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26795,"kind":"person","name":"Yanez Michelle","position":1,"cik":"0001958023","reported_name":"Yanez Michelle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-04T16:19:04.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval."}],"balance_after":1221271,"source":{"system":"sec-edgar","filing":"0001493152-26-035955","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315226035955/ownership.xml","form_type":"4"}},{"id":697763,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26794,"kind":"person","name":"SEARS SAMUEL P JR","position":1,"cik":"0001238483","reported_name":"SEARS SAMUEL P JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-04T16:15:19.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval."}],"balance_after":1229543,"source":{"system":"sec-edgar","filing":"0001493152-26-035953","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315226035953/ownership.xml","form_type":"4"}},{"id":697845,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26815,"kind":"person","name":"ODONNELL FRANCIS E JR","position":1,"cik":"0001066040","reported_name":"ODONNELL FRANCIS E JR","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-04T15:55:47.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0001493152-26-035950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1066040/000149315226035950/ownership.xml","form_type":"4"}},{"id":728062,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":28608,"kind":"person","name":"Jerman Michael Allen","position":1,"cik":"0001979732","reported_name":"Jerman Michael Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T16:34:53.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan."}],"balance_after":180411,"source":{"system":"sec-edgar","filing":"0001493152-26-029898","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315226029898/ownership.xml","form_type":"4"}},{"id":757621,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":42896,"kind":"person","name":"Vasisht Niraj","position":1,"cik":"0001662930","reported_name":"Vasisht Niraj","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T20:15:25.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001493152-26-026623","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315226026623/ownership.xml","form_type":"4"}},{"id":1174280,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":42896,"kind":"person","name":"Vasisht Niraj","position":1,"cik":"0001662930","reported_name":"Vasisht Niraj","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-10T17:30:33.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan."}],"source":{"system":"sec-edgar","filing":"0001641172-25-003556","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000164117225003556/ownership.xml","form_type":"4"}},{"id":1176942,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26795,"kind":"person","name":"Yanez Michelle","position":1,"cik":"0001958023","reported_name":"Yanez Michelle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-07T21:25:09.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan."}],"balance_after":896271,"source":{"system":"sec-edgar","filing":"0001641172-25-003033","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000164117225003033/ownership.xml","form_type":"4"}},{"id":1176941,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26794,"kind":"person","name":"SEARS SAMUEL P JR","position":1,"cik":"0001238483","reported_name":"SEARS SAMUEL P JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-07T21:23:08.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan."}],"balance_after":1279543,"source":{"system":"sec-edgar","filing":"0001641172-25-003029","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000164117225003029/ownership.xml","form_type":"4"}},{"id":1176940,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26796,"kind":"person","name":"OSMAN RONALD E","position":1,"cik":"0001380466","reported_name":"OSMAN RONALD E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26797,"kind":"organization","name":"Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012","position":2,"cik":"0001972372","reported_name":"Ronald E Osman Irrevocable Trust III","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-07T21:22:03.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares represent 100,000 shares owned by Mr. Osman and remaining number of shares of common stock held by The Ronald E. Osman Trust III. Mr. Osman is the sole trustee of the Ronald E. Osman Trust III."}],"balance_after":23554985,"source":{"system":"sec-edgar","filing":"0001641172-25-003025","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000164117225003025/ownership.xml","form_type":"4"}},{"id":1176936,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":28608,"kind":"person","name":"Jerman Michael Allen","position":1,"cik":"0001979732","reported_name":"Jerman Michael Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-07T21:21:06.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan."}],"balance_after":80411,"source":{"system":"sec-edgar","filing":"0001641172-25-003023","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000164117225003023/ownership.xml","form_type":"4"}},{"id":1261185,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26799,"kind":"person","name":"MCNULTY JAMES A","position":1,"cik":"0001275857","reported_name":"MCNULTY JAMES A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-20T02:28:48.000Z","date":"2024-12-02","kind":"gift","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1946135,"source":{"system":"sec-edgar","filing":"0001493152-25-007628","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315225007628/ownership.xml","form_type":"5"}},{"id":1261181,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26795,"kind":"person","name":"Yanez Michelle","position":1,"cik":"0001958023","reported_name":"Yanez Michelle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-20T02:27:39.000Z","date":"2024-12-02","kind":"gift","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1146271,"source":{"system":"sec-edgar","filing":"0001493152-25-007626","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315225007626/ownership.xml","form_type":"5"}},{"id":1514710,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26795,"kind":"person","name":"Yanez Michelle","position":1,"cik":"0001958023","reported_name":"Yanez Michelle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-16T17:34:39.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan."}],"balance_after":896271,"source":{"system":"sec-edgar","filing":"0001493152-24-020171","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315224020171/ownership.xml","form_type":"4"}},{"id":1514709,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26799,"kind":"person","name":"MCNULTY JAMES A","position":1,"cik":"0001275857","reported_name":"MCNULTY JAMES A","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option","published_at":"2024-05-16T17:34:37.000Z","date":"2024-03-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The common stock options were issued to the Reporting Person on March 16, 2024 pursuant to the Issuer's 2014 Equity Incentive Plan. The common stock options vested immediately."}],"balance_after":100000,"derivative":{"exercise_price":0.08,"expiration_date":"2034-03-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-24-020169","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315224020169/ownership.xml","form_type":"4"}},{"id":1514707,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26794,"kind":"person","name":"SEARS SAMUEL P JR","position":1,"cik":"0001238483","reported_name":"SEARS SAMUEL P JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-16T17:34:35.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan."}],"balance_after":1129543,"source":{"system":"sec-edgar","filing":"0001493152-24-020173","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315224020173/ownership.xml","form_type":"4"}},{"id":1514708,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26796,"kind":"person","name":"OSMAN RONALD E","position":1,"cik":"0001380466","reported_name":"OSMAN RONALD E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26797,"kind":"organization","name":"Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012","position":2,"cik":"0001972372","reported_name":"Ronald E Osman Irrevocable Trust III","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-16T17:34:32.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Seefootnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares represent 100,000 shares owned by Mr. Osman and remaining number of shares of common stock held by The Ronald E. Osman Trust III. Mr. Osman is the sole trustee of the Ronald E. Osman Trust III."}],"balance_after":23564985,"source":{"system":"sec-edgar","filing":"0001493152-24-020172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315224020172/ownership.xml","form_type":"4"}},{"id":1514706,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":28608,"kind":"person","name":"Jerman Michael Allen","position":1,"cik":"0001979732","reported_name":"Jerman Michael Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-16T17:34:29.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan."}],"balance_after":80411,"source":{"system":"sec-edgar","filing":"0001493152-24-020170","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000149315224020170/ownership.xml","form_type":"4"}},{"id":1794450,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26796,"kind":"person","name":"OSMAN RONALD E","position":1,"cik":"0001380466","reported_name":"OSMAN RONALD E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26797,"kind":"organization","name":"Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012","position":2,"cik":"0001972372","reported_name":"Ronald E Osman Irrevocable Trust III","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-29T19:49:19.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant from the company for no consideration"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares represent 25,000 shares owned by Mr. Osman and remaining number of shares of common stock held  by The Ronald E. Osman Trust III. Mr. Osman is the sole trustee of the Ronald E. Osman Trust III."}],"balance_after":23514985,"source":{"system":"sec-edgar","filing":"0000950170-23-045043","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000095017023045043/ownership.xml","form_type":"4"}},{"id":1889766,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26799,"kind":"person","name":"MCNULTY JAMES A","position":1,"cik":"0001275857","reported_name":"MCNULTY JAMES A","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-05-17T23:46:15.000Z","date":"2023-05-05","kind":"other","planned":false,"acquired":true,"shares":20101057,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC (\"HPLLC\"), pro-rata pursuant to their membership interest in HPLLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. McNulty was the manager of HPLLC, which distributed 79,627,069 shares of common stock to its members, pro-rata pursuant to their membership interest in HPLLC. Pursuant to the distribution, Mr. McNulty received 398,135 shares of common stock and Blackrobe Capital LLC received 20,101,057 shares of common stock. Mr. McNulty is the sole manager of Blackrobe Capital, LLC, but has no pecuniary interest in such shares."}],"balance_after":26101057,"source":{"system":"sec-edgar","filing":"0000899243-23-013201","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924323013201/doc4.xml","form_type":"4"}},{"id":1889765,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26799,"kind":"person","name":"MCNULTY JAMES A","position":1,"cik":"0001275857","reported_name":"MCNULTY JAMES A","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-05-17T23:46:15.000Z","date":"2023-05-05","kind":"other","planned":false,"acquired":true,"shares":398135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC (\"HPLLC\"), pro-rata pursuant to their membership interest in HPLLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Mr. McNulty was the manager of HPLLC, which distributed 79,627,069 shares of common stock to its members, pro-rata pursuant to their membership interest in HPLLC. Pursuant to the distribution, Mr. McNulty received 398,135 shares of common stock and Blackrobe Capital LLC received 20,101,057 shares of common stock. Mr. McNulty is the sole manager of Blackrobe Capital, LLC, but has no pecuniary interest in such shares."}],"balance_after":946135,"source":{"system":"sec-edgar","filing":"0000899243-23-013201","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924323013201/doc4.xml","form_type":"4"}},{"id":1889764,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26799,"kind":"person","name":"MCNULTY JAMES A","position":1,"cik":"0001275857","reported_name":"MCNULTY JAMES A","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-05-17T23:46:15.000Z","date":"2023-05-05","kind":"other","planned":false,"acquired":false,"shares":79627069,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC (\"HPLLC\"), pro-rata pursuant to their membership interest in HPLLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. McNulty was the manager of HPLLC, which distributed 79,627,069 shares of common stock to its members, pro-rata pursuant to their membership interest in HPLLC. Pursuant to the distribution, Mr. McNulty received 398,135 shares of common stock and Blackrobe Capital LLC received 20,101,057 shares of common stock. Mr. McNulty is the sole manager of Blackrobe Capital, LLC, but has no pecuniary interest in such shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-013201","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924323013201/doc4.xml","form_type":"4"}},{"id":1889763,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":26795,"kind":"person","name":"Yanez Michelle","position":1,"cik":"0001958023","reported_name":"Yanez Michelle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-17T23:09:26.000Z","date":"2023-05-05","kind":"other","planned":false,"acquired":true,"shares":796271,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC (\"HPLLC\"), pro-rata pursuant to their membership interest in HPLLC."}],"balance_after":800673,"source":{"system":"sec-edgar","filing":"0000899243-23-013195","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924323013195/doc4.xml","form_type":"4"}},{"id":2904807,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-19T18:50:50.000Z","date":"2021-01-15","kind":"other","acquired":true,"shares":2240488,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 15, 2021, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") received a dividend of 2,240,488 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures may be deemed to be a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":204083227,"source":{"system":"sec-edgar","filing":"0001104659-21-005226","document":"tm213575d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000110465921005226/tm213575d1_4.xml","form_type":"4"}},{"id":2931730,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144376,"kind":"person","name":"Hasara Garrison J.","position":1,"cik":"0001510349","reported_name":"Hasara Garrison J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock Option","published_at":"2020-12-28T21:30:36.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":125000,"derivative":{"exercise_price":0.031,"exercise_date":"2020-12-22","expiration_date":"2030-12-22","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000899243-20-035203","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320035203/doc4.xml","form_type":"4"}},{"id":2931729,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2020-12-28T21:30:32.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":1306452,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1306452,"derivative":{"exercise_price":0.031,"exercise_date":"2020-12-22","expiration_date":"2030-12-22","underlying":"Common Stock","underlying_shares":1306452},"source":{"system":"sec-edgar","filing":"0000899243-20-035202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320035202/doc4.xml","form_type":"4"}},{"id":2931728,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":41246,"kind":"person","name":"Ono Richard Dana","position":1,"cik":"0001595989","reported_name":"Ono Richard Dana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2020-12-28T21:30:31.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":754839,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":754839,"derivative":{"exercise_price":0.031,"exercise_date":"2020-12-22","expiration_date":"2030-12-22","underlying":"Common Stock","underlying_shares":754839},"source":{"system":"sec-edgar","filing":"0000899243-20-035201","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320035201/doc4.xml","form_type":"4"}},{"id":2931727,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144375,"kind":"person","name":"Peattie Debra","position":1,"cik":"0001792108","reported_name":"Peattie Debra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2020-12-28T21:30:29.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":580646,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":580646,"derivative":{"exercise_price":0.031,"exercise_date":"2020-12-22","expiration_date":"2030-12-22","underlying":"Common Stock","underlying_shares":580646},"source":{"system":"sec-edgar","filing":"0000899243-20-035200","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320035200/doc4.xml","form_type":"4"}},{"id":2931726,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144374,"kind":"person","name":"VIRCA NICHOLAS J","position":1,"cik":"0001284074","reported_name":"VIRCA NICHOLAS J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock Option","published_at":"2020-12-28T21:30:23.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":125000,"derivative":{"exercise_price":0.031,"exercise_date":"2020-12-22","expiration_date":"2030-12-22","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000899243-20-035197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320035197/doc4.xml","form_type":"4"}},{"id":2931725,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144373,"kind":"person","name":"Martin Robert Daniel","position":1,"cik":"0001509322","reported_name":"Martin Robert Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2020-12-28T21:30:11.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":754839,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":754839,"derivative":{"exercise_price":0.031,"exercise_date":"2020-12-22","expiration_date":"2030-12-22","underlying":"Common Stock","underlying_shares":754839},"source":{"system":"sec-edgar","filing":"0000899243-20-035195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320035195/doc4.xml","form_type":"4"}},{"id":3026255,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144374,"kind":"person","name":"VIRCA NICHOLAS J","position":1,"cik":"0001284074","reported_name":"VIRCA NICHOLAS J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock Option","published_at":"2020-09-21T22:42:28.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":0.054,"exercise_date":"2020-09-17","expiration_date":"2030-09-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-20-025807","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320025807/doc4.xml","form_type":"4"}},{"id":3026254,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144376,"kind":"person","name":"Hasara Garrison J.","position":1,"cik":"0001510349","reported_name":"Hasara Garrison J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock Option","published_at":"2020-09-21T22:39:24.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":0.054,"exercise_date":"2020-09-17","expiration_date":"2030-09-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-20-025806","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320025806/doc4.xml","form_type":"4"}},{"id":3079741,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-21T01:56:46.000Z","date":"2020-07-15","kind":"other","acquired":true,"shares":3189688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 15, 2020, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") received a dividend of 3,189,688 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures may be deemed to be a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":201842739,"source":{"system":"sec-edgar","filing":"0001104659-20-084975","document":"tm2025270d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000110465920084975/tm2025270d1_4.xml","form_type":"4"}},{"id":3196753,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":41246,"kind":"person","name":"Ono Richard Dana","position":1,"cik":"0001595989","reported_name":"Ono Richard Dana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2020-03-24T13:02:47.000Z","date":"2020-03-20","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1000000,"derivative":{"exercise_price":0.05,"exercise_date":"2021-03-20","expiration_date":"2030-03-20","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-20-009312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320009312/doc4.xml","form_type":"4"}},{"id":3196754,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144375,"kind":"person","name":"Peattie Debra","position":1,"cik":"0001792108","reported_name":"Peattie Debra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2020-03-24T13:01:09.000Z","date":"2020-03-20","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1000000,"derivative":{"exercise_price":0.05,"exercise_date":"2021-03-20","expiration_date":"2030-03-20","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-20-009310","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320009310/doc4.xml","form_type":"4"}},{"id":3196752,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144373,"kind":"person","name":"Martin Robert Daniel","position":1,"cik":"0001509322","reported_name":"Martin Robert Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2020-03-24T13:00:41.000Z","date":"2020-03-20","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1000000,"derivative":{"exercise_price":0.05,"exercise_date":"2021-03-20","expiration_date":"2030-03-20","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-20-009309","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320009309/doc4.xml","form_type":"4"}},{"id":3196751,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2020-03-24T13:00:23.000Z","date":"2020-03-20","kind":"grant","acquired":true,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1500000,"derivative":{"exercise_price":0.05,"exercise_date":"2021-03-20","expiration_date":"2030-03-20","underlying":"Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0000899243-20-009308","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320009308/doc4.xml","form_type":"4"}},{"id":3282859,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-10T21:20:28.000Z","date":"2019-12-12","kind":"purchase","acquired":true,"shares":500,"price":0.0619,"value":30.95,"ownership":{"direct":true},"balance_after":1054100,"source":{"system":"sec-edgar","filing":"0000899243-20-003818","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924320003818/doc5.xml","form_type":"5"}},{"id":3341216,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144375,"kind":"person","name":"Peattie Debra","position":1,"cik":"0001792108","reported_name":"Peattie Debra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2019-12-16T21:32:10.000Z","date":"2019-12-12","kind":"grant","acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":210000,"derivative":{"exercise_price":0.05,"exercise_date":"2020-02-03","expiration_date":"2029-12-12","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0000899243-19-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924319029254/doc4.xml","form_type":"4"}},{"id":3356098,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144376,"kind":"person","name":"Hasara Garrison J.","position":1,"cik":"0001510349","reported_name":"Hasara Garrison J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2019-12-03T01:57:29.000Z","date":"2019-12-02","kind":"purchase","acquired":true,"shares":13500,"price":0.07,"value":945.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in two transactions at a per share price equal to $0.07 and $0.068. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3972544,"source":{"system":"sec-edgar","filing":"0000899243-19-028374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924319028374/doc4.xml","form_type":"4"}},{"id":3496073,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2019-06-10T22:27:08.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":0.073,"exercise_date":"2020-02-03","expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-19-016242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924319016242/doc4.xml","form_type":"4"}},{"id":3674990,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":41246,"kind":"person","name":"Ono Richard Dana","position":1,"cik":"0001595989","reported_name":"Ono Richard Dana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2019-02-06T00:57:48.000Z","date":"2019-02-03","kind":"grant","acquired":true,"shares":657895,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":657895,"derivative":{"exercise_price":0.076,"exercise_date":"2020-02-03","expiration_date":"2029-02-03","underlying":"Common Stock","underlying_shares":657895},"source":{"system":"sec-edgar","filing":"0000899243-19-002715","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924319002715/doc4.xml","form_type":"4"}},{"id":3674991,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144373,"kind":"person","name":"Martin Robert Daniel","position":1,"cik":"0001509322","reported_name":"Martin Robert Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2019-02-06T00:57:47.000Z","date":"2019-02-03","kind":"grant","acquired":true,"shares":657895,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":657895,"derivative":{"exercise_price":0.076,"exercise_date":"2020-02-03","expiration_date":"2029-02-03","underlying":"Common Stock","underlying_shares":657895},"source":{"system":"sec-edgar","filing":"0000899243-19-002714","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924319002714/doc4.xml","form_type":"4"}},{"id":3674988,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2019-02-06T00:54:44.000Z","date":"2019-02-03","kind":"grant","acquired":true,"shares":657895,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":657895,"derivative":{"exercise_price":0.076,"exercise_date":"2020-02-03","expiration_date":"2029-02-03","underlying":"Common Stock","underlying_shares":657895},"source":{"system":"sec-edgar","filing":"0000899243-19-002712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924319002712/doc4.xml","form_type":"4"}},{"id":3674989,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":160588,"kind":"person","name":"MAGRAB E. BRENDAN","position":1,"cik":"0001196062","reported_name":"MAGRAB E. BRENDAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options","published_at":"2019-02-06T00:52:27.000Z","date":"2019-02-03","kind":"grant","acquired":true,"shares":986842,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":986842,"derivative":{"exercise_price":0.076,"exercise_date":"2020-02-03","expiration_date":"2029-02-03","underlying":"Common Stock","underlying_shares":986842},"source":{"system":"sec-edgar","filing":"0000899243-19-002708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924319002708/doc4.xml","form_type":"4"}},{"id":3688263,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-25T00:49:58.000Z","date":"2019-01-15","kind":"other","acquired":true,"shares":362121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 15, 2019, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") received a dividend of 362,121 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":198653051,"source":{"system":"sec-edgar","filing":"0001144204-19-002698","document":"tv511589_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420419002698/tv511589_4.xml","form_type":"4"}},{"id":3719818,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144373,"kind":"person","name":"Martin Robert Daniel","position":1,"cik":"0001509322","reported_name":"Martin Robert Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-26T22:15:23.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":60000,"price":0.08,"value":4800.0,"ownership":{"direct":true},"balance_after":116000,"source":{"system":"sec-edgar","filing":"0000899243-18-031719","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924318031719/doc4.xml","form_type":"4"}},{"id":3719815,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":160588,"kind":"person","name":"MAGRAB E. BRENDAN","position":1,"cik":"0001196062","reported_name":"MAGRAB E. BRENDAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-26T22:15:21.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":65000,"price":0.08,"value":5200.0,"ownership":{"direct":true},"balance_after":65000,"source":{"system":"sec-edgar","filing":"0000899243-18-031718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924318031718/doc4.xml","form_type":"4"}},{"id":3725317,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-19T11:09:33.000Z","date":"2018-07-15","kind":"other","acquired":true,"shares":184798,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 15, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") received a dividend of 184,798 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":198290930,"source":{"system":"sec-edgar","filing":"0001144204-18-065264","document":"tv509462_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418065264/tv509462_4.xml","form_type":"4"}},{"id":3828946,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144376,"kind":"person","name":"Hasara Garrison J.","position":1,"cik":"0001510349","reported_name":"Hasara Garrison J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2018-08-31T20:30:31.000Z","date":"2018-08-30","kind":"sale","acquired":false,"shares":100000,"price":0.27,"value":27000.0,"ownership":{"direct":true},"balance_after":3959044,"source":{"system":"sec-edgar","filing":"0000899243-18-023650","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924318023650/doc4.xml","form_type":"4"}},{"id":3871929,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants to Purchase Common Stock","published_at":"2018-07-06T21:11:47.000Z","date":"2018-07-05","kind":"purchase","acquired":true,"shares":1739131,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B warrants have an initial exercise price of US$0.275 and may be exercised by Mayne Ventures at any time prior to their expiration on July 5, 2023."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B warrants have an initial exercise price of US$0.275 and may be exercised by Mayne Ventures at any time prior to their expiration on July 5, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":1739131,"derivative":{"exercise_price":0.275,"exercise_date":"2018-07-05","expiration_date":"2023-07-05","underlying":"Common Stock","underlying_shares":1739131},"source":{"system":"sec-edgar","filing":"0001144204-18-037560","document":"tv498045_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418037560/tv498045_4.xml","form_type":"4"}},{"id":3871928,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants to Purchase Common Stock","published_at":"2018-07-06T21:11:47.000Z","date":"2018-07-05","kind":"purchase","acquired":true,"shares":1739131,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A warrants have an initial exercise price of US$0.23 and may be exercised by Mayne Ventures at any time prior to their expiration on July 5, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A warrants have an initial exercise price of US$0.23 and may be exercised by Mayne Ventures at any time prior to their expiration on July 5, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":1739131,"derivative":{"exercise_price":0.23,"exercise_date":"2018-07-05","expiration_date":"2020-07-05","underlying":"Common Stock","underlying_shares":1739131},"source":{"system":"sec-edgar","filing":"0001144204-18-037560","document":"tv498045_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418037560/tv498045_4.xml","form_type":"4"}},{"id":3871927,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-07-06T21:11:47.000Z","date":"2018-07-05","kind":"purchase","acquired":true,"shares":2318841,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 5, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired (i) 2,318,841 shares of Series B Convertible Preferred Stock, (ii) Series A warrants to purchase 1,739,131 shares of Common Stock in the aggregate and (iii) Series B warrants to purchase 1,739,131 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$1,600,000 at the second closing pursuant to the terms of the securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":5797102,"derivative":{"exercise_date":"2018-07-05","underlying":"Common Stock","underlying_shares":6956523},"source":{"system":"sec-edgar","filing":"0001144204-18-037560","document":"tv498045_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418037560/tv498045_4.xml","form_type":"4"}},{"id":3994954,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144373,"kind":"person","name":"Martin Robert Daniel","position":1,"cik":"0001509322","reported_name":"Martin Robert Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2018-03-16T00:15:01.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":56000,"derivative":{"exercise_price":0.2722,"exercise_date":"2018-03-13","expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0000899243-18-007662","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924318007662/doc4.xml","form_type":"4"}},{"id":3994953,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144373,"kind":"person","name":"Martin Robert Daniel","position":1,"cik":"0001509322","reported_name":"Martin Robert Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2018-03-16T00:15:01.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":253000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These options were granted subject to the approval of the majority stockholder of the registrant pursuant to an agreement between the majority stockholder and the registrant. In the event that the majority stockholder does not approve the option grant, the options will be canceled."}],"balance_after":253000,"derivative":{"exercise_price":0.2722,"exercise_date":"2019-03-13","expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":253000},"source":{"system":"sec-edgar","filing":"0000899243-18-007662","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924318007662/doc4.xml","form_type":"4"}},{"id":3994952,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":160588,"kind":"person","name":"MAGRAB E. BRENDAN","position":1,"cik":"0001196062","reported_name":"MAGRAB E. BRENDAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Common Stock Options","published_at":"2018-03-15T22:39:26.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":345000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These options were granted subject to the approval of the majority stockholder of the registrant pursuant to an agreement between the majority stockholder and the registrant. In the event that the majority stockholder does not approve the option grant, the options will be canceled."}],"balance_after":345000,"derivative":{"exercise_price":0.2722,"exercise_date":"2019-03-13","expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":345000},"source":{"system":"sec-edgar","filing":"0000899243-18-007628","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924318007628/doc4.xml","form_type":"4"}},{"id":3994951,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":41246,"kind":"person","name":"Ono Richard Dana","position":1,"cik":"0001595989","reported_name":"Ono Richard Dana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2018-03-15T21:07:02.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":56000,"derivative":{"exercise_price":0.2722,"exercise_date":"2018-03-13","expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0000899243-18-007587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924318007587/doc4.xml","form_type":"4"}},{"id":3994950,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":41246,"kind":"person","name":"Ono Richard Dana","position":1,"cik":"0001595989","reported_name":"Ono Richard Dana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2018-03-15T21:07:02.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":253000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These options were granted subject to the approval of the majority stockholder of the registrant pursuant to an agreement between the majority stockholder and the registrant. In the event that the majority stockholder does not approve the option grant, the options will be canceled."}],"balance_after":253000,"derivative":{"exercise_price":0.2722,"exercise_date":"2019-03-13","expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":253000},"source":{"system":"sec-edgar","filing":"0000899243-18-007587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924318007587/doc4.xml","form_type":"4"}},{"id":3994949,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2018-03-15T21:01:40.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":76000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":76000,"derivative":{"exercise_price":0.2722,"exercise_date":"2018-03-13","expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":76000},"source":{"system":"sec-edgar","filing":"0000899243-18-007585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924318007585/doc4.xml","form_type":"4"}},{"id":3994948,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2018-03-15T21:01:40.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":253000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These options were granted subject to the approval of the majority stockholder of the registrant pursuant to an agreement between the majority stockholder and the registrant. In the event that the majority stockholder does not approve the option grant, the options will be canceled."}],"balance_after":253000,"derivative":{"exercise_price":0.2722,"exercise_date":"2019-03-13","expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":253000},"source":{"system":"sec-edgar","filing":"0000899243-18-007585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924318007585/doc4.xml","form_type":"4"}},{"id":3994947,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144376,"kind":"person","name":"Hasara Garrison J.","position":1,"cik":"0001510349","reported_name":"Hasara Garrison J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock Option","published_at":"2018-03-15T21:00:38.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":260000,"derivative":{"exercise_price":0.2722,"exercise_date":"2018-03-13","expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0000899243-18-007584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924318007584/doc4.xml","form_type":"4"}},{"id":3994946,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144374,"kind":"person","name":"VIRCA NICHOLAS J","position":1,"cik":"0001284074","reported_name":"VIRCA NICHOLAS J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock Option","published_at":"2018-03-15T21:00:30.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":310000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":310000,"derivative":{"exercise_price":0.2722,"exercise_date":"2018-03-13","expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0000899243-18-007583","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924318007583/doc4.xml","form_type":"4"}},{"id":4066473,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":169549,"kind":"person","name":"Cross Stefan","position":1,"cik":"0001611506","reported_name":"Cross Stefan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-13T01:00:15.000Z","date":"2017-12-19","kind":"purchase","acquired":false,"shares":600000,"price":162660,"value":97596000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 19, 2017, Stefan Cross sold 600,000 shares of Common Stock to Mayne Pharma Ventures Pty Ltd."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001144204-18-007442","document":"tv485758_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418007442/tv485758_4.xml","form_type":"4"}},{"id":4066472,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-02-13T00:47:01.000Z","date":"2017-12-19","kind":"purchase","acquired":true,"shares":600000,"price":162660,"value":97596000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 19, 2017, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 600,000 shares of Common Stock from Stefan Cross."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":198106132,"source":{"system":"sec-edgar","filing":"0001144204-18-007440","document":"tv485756_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418007440/tv485756_4.xml","form_type":"4"}},{"id":4101477,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants to Purchase Common Stock","published_at":"2018-01-11T14:21:42.000Z","date":"2018-01-10","kind":"purchase","acquired":true,"shares":2608696,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B warrants have an initial exercise price of US$0.275 and may be exercised by Mayne Ventures at any time prior to their expiration on January 10, 2023."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B warrants have an initial exercise price of US$0.275 and may be exercised by Mayne Ventures at any time prior to their expiration on January 10, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":2608696,"derivative":{"exercise_price":0.275,"exercise_date":"2018-01-10","expiration_date":"2023-01-10","underlying":"Common Stock","underlying_shares":2608696},"source":{"system":"sec-edgar","filing":"0001144204-18-001823","document":"tv483130_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418001823/tv483130_4.xml","form_type":"4"}},{"id":4101476,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants to Purchase Common Stock","published_at":"2018-01-11T14:21:42.000Z","date":"2018-01-10","kind":"purchase","acquired":true,"shares":2608696,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A warrants have an initial exercise price of US$0.23 and may be exercised by Mayne Ventures at any time prior to their expiration on January 10, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A warrants have an initial exercise price of US$0.23 and may be exercised by Mayne Ventures at any time prior to their expiration on January 10, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":2608696,"derivative":{"exercise_price":0.23,"exercise_date":"2018-01-10","expiration_date":"2020-01-10","underlying":"Common Stock","underlying_shares":2608696},"source":{"system":"sec-edgar","filing":"0001144204-18-001823","document":"tv483130_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418001823/tv483130_4.xml","form_type":"4"}},{"id":4101475,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":143703,"kind":"organization","name":"Mayne Pharma Ventures Pty Ltd","position":1,"cik":"0001611535","reported_name":"Mayne Pharma Ventures Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143704,"kind":"organization","name":"Mayne Pharma International Pty Ltd","position":2,"cik":"0001611534","reported_name":"Mayne Pharma International Pty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143705,"kind":"organization","name":"Mayne Pharma Group Ltd","position":3,"cik":"0001560183","reported_name":"Mayne Pharma Group Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-01-11T14:21:42.000Z","date":"2018-01-10","kind":"purchase","acquired":true,"shares":3478261,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 10, 2018, Mayne Pharma Ventures Pty Ltd (\"Mayne Ventures\") acquired 3,478,261 shares of Series B Convertible Preferred Stock, Series A warrants to purchase 2,608,696 shares of Common Stock in the aggregate and Series B warrants to purchase 2,608,696 shares of Common Stock directly from the Issuer in a private placement for an aggregate purchase price of US$2,400,000 pursuant to the terms of a securities purchase agreement, dated January 8, 2018, between Mayne Ventures and the Issuer. Each share of Series B Convertible Preferred Stock (i) may be converted by Mayne Ventures at any time into three shares of Common Stock and (ii) is entitled to the number of votes equal to the number of shares of Common Stock into which each such share of Series B Convertible Preferred Stock is convertible. The Series B Convertible Preferred Stock does not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd (\"Mayne International\") and Mayne Pharma Group Limited (\"Mayne Group\"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer."}],"balance_after":3478261,"derivative":{"exercise_date":"2018-01-10","underlying":"Common Stock","underlying_shares":10434783},"source":{"system":"sec-edgar","filing":"0001144204-18-001823","document":"tv483130_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000114420418001823/tv483130_4.xml","form_type":"4"}},{"id":4254756,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144373,"kind":"person","name":"Martin Robert Daniel","position":1,"cik":"0001509322","reported_name":"Martin Robert Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-07-19T23:43:12.000Z","date":"2017-05-04","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs were issued to the reporting person on May 4, 2017, pursuant to a grant under the issuer's 2014 Equity Incentive Plan. The RSUs will vest in full on January 1, 2018, provided that if such vesting date is not during an open trading window, then such RSUs will vest on the first day that thereafter that is during an open trading window."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs were issued to the reporting person on May 4, 2017, pursuant to a grant under the issuer's 2014 Equity Incentive Plan. The RSUs will vest in full on January 1, 2018, provided that if such vesting date is not during an open trading window, then such RSUs will vest on the first day that thereafter that is during an open trading window."}],"balance_after":60000,"derivative":{"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-17-018594","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317018594/doc4.xml","form_type":"4"}},{"id":4254755,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":160588,"kind":"person","name":"MAGRAB E. BRENDAN","position":1,"cik":"0001196062","reported_name":"MAGRAB E. BRENDAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Restricted Stock Units","published_at":"2017-07-19T23:41:15.000Z","date":"2017-05-04","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs were issued to the reporting person on May 4, 2017, pursuant to a grant under the issuer's 2014 Equity Incentive Plan. The RSUs will vest in full on January 1, 2018, provided that if such vesting date is not during an open trading window, then such RSUs will vest on the first day that thereafter that is during an open trading window."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs were issued to the reporting person on May 4, 2017, pursuant to a grant under the issuer's 2014 Equity Incentive Plan. The RSUs will vest in full on January 1, 2018, provided that if such vesting date is not during an open trading window, then such RSUs will vest on the first day that thereafter that is during an open trading window."}],"balance_after":65000,"derivative":{"underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000899243-17-018593","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317018593/doc4.xml","form_type":"4"}},{"id":4258559,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":174468,"kind":"organization","name":"HedgePath, LLC","position":1,"cik":"0001584617","reported_name":"HedgePath, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $.0001 par value per share","published_at":"2017-07-12T20:05:31.000Z","date":"2017-06-30","kind":"sale","acquired":false,"shares":2500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 30, 2017, the Reporting Person sold 2,500,000 shares of restricted common stock in a private transaction to an unaffiliated third party for a total purchase price of $500,000."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2017, the Reporting Person sold 2,500,000 shares of restricted common stock in a private transaction to an unaffiliated third party for a total purchase price of $500,000."}],"balance_after":79627069,"source":{"system":"sec-edgar","filing":"0000899243-17-018211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317018211/doc4.xml","form_type":"4"}},{"id":4391056,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-03-10T21:19:41.000Z","date":"2017-03-08","kind":"exercise","acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs were issued to the reporting person on July 1, 2016, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs were issued to the reporting person on July 1, 2016, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-17-007154","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007154/doc4.xml","form_type":"4"}},{"id":4391055,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-03-10T21:19:41.000Z","date":"2017-03-08","kind":"exercise","acquired":false,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000899243-17-007154","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007154/doc4.xml","form_type":"4"}},{"id":4391054,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-03-10T21:19:41.000Z","date":"2017-03-08","kind":"exercise","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-17-007154","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007154/doc4.xml","form_type":"4"}},{"id":4391053,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-10T21:19:41.000Z","date":"2017-03-08","kind":"tax_withholding","acquired":false,"shares":79200,"price":0.34,"value":26928.0,"ownership":{"direct":true},"balance_after":553600,"source":{"system":"sec-edgar","filing":"0000899243-17-007154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007154/doc4.xml","form_type":"4"}},{"id":4391052,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-10T21:19:41.000Z","date":"2017-03-08","kind":"exercise","acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The RSUs were issued to the reporting person on July 1, 2016, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":632800,"source":{"system":"sec-edgar","filing":"0000899243-17-007154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007154/doc4.xml","form_type":"4"}},{"id":4391051,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-10T21:19:41.000Z","date":"2017-03-08","kind":"tax_withholding","acquired":false,"shares":158400,"price":0.34,"value":53856.0,"ownership":{"direct":true},"balance_after":432800,"source":{"system":"sec-edgar","filing":"0000899243-17-007154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007154/doc4.xml","form_type":"4"}},{"id":4391050,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-10T21:19:41.000Z","date":"2017-03-08","kind":"exercise","acquired":true,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":591200,"source":{"system":"sec-edgar","filing":"0000899243-17-007154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007154/doc4.xml","form_type":"4"}},{"id":4391049,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-10T21:19:41.000Z","date":"2017-03-08","kind":"tax_withholding","acquired":false,"shares":118800,"price":0.34,"value":40392.0,"ownership":{"direct":true},"balance_after":191200,"source":{"system":"sec-edgar","filing":"0000899243-17-007154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007154/doc4.xml","form_type":"4"}},{"id":4391048,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":29982,"kind":"person","name":"Watson W. Mark","position":1,"cik":"0001612372","reported_name":"Watson W. Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-10T21:19:41.000Z","date":"2017-03-08","kind":"exercise","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":310000,"source":{"system":"sec-edgar","filing":"0000899243-17-007154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007154/doc4.xml","form_type":"4"}},{"id":4391044,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144376,"kind":"person","name":"Hasara Garrison J.","position":1,"cik":"0001510349","reported_name":"Hasara Garrison J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Restricted Stock Units","published_at":"2017-03-10T21:17:14.000Z","date":"2017-03-08","kind":"exercise","acquired":false,"shares":3500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs were issued to the reporting person on August 6, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs were issued to the reporting person on August 6, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3500000},"source":{"system":"sec-edgar","filing":"0000899243-17-007153","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007153/doc4.xml","form_type":"4"}},{"id":4391043,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144376,"kind":"person","name":"Hasara Garrison J.","position":1,"cik":"0001510349","reported_name":"Hasara Garrison J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Restricted Stock Units","published_at":"2017-03-10T21:17:14.000Z","date":"2017-03-08","kind":"exercise","acquired":false,"shares":3500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs were issued to the reporting person on August 6, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs were issued to the reporting person on August 6, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3500000},"source":{"system":"sec-edgar","filing":"0000899243-17-007153","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007153/doc4.xml","form_type":"4"}},{"id":4391042,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144376,"kind":"person","name":"Hasara Garrison J.","position":1,"cik":"0001510349","reported_name":"Hasara Garrison J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2017-03-10T21:17:14.000Z","date":"2017-03-08","kind":"tax_withholding","acquired":false,"shares":1470478,"price":0.34,"value":499962.52,"ownership":{"direct":true},"balance_after":4059044,"source":{"system":"sec-edgar","filing":"0000899243-17-007153","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007153/doc4.xml","form_type":"4"}},{"id":4391041,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144376,"kind":"person","name":"Hasara Garrison J.","position":1,"cik":"0001510349","reported_name":"Hasara Garrison J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2017-03-10T21:17:14.000Z","date":"2017-03-08","kind":"exercise","acquired":true,"shares":3500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were issued to the reporting person on August 6, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":5529522,"source":{"system":"sec-edgar","filing":"0000899243-17-007153","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007153/doc4.xml","form_type":"4"}},{"id":4391040,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144376,"kind":"person","name":"Hasara Garrison J.","position":1,"cik":"0001510349","reported_name":"Hasara Garrison J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2017-03-10T21:17:14.000Z","date":"2017-03-08","kind":"tax_withholding","acquired":false,"shares":1470478,"price":0.34,"value":499962.52,"ownership":{"direct":true},"balance_after":2029522,"source":{"system":"sec-edgar","filing":"0000899243-17-007153","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007153/doc4.xml","form_type":"4"}},{"id":4391039,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144376,"kind":"person","name":"Hasara Garrison J.","position":1,"cik":"0001510349","reported_name":"Hasara Garrison J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2017-03-10T21:17:14.000Z","date":"2017-03-08","kind":"exercise","acquired":true,"shares":3500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were issued to the reporting person on August 6, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":3500000,"source":{"system":"sec-edgar","filing":"0000899243-17-007153","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007153/doc4.xml","form_type":"4"}},{"id":4391047,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144374,"kind":"person","name":"VIRCA NICHOLAS J","position":1,"cik":"0001284074","reported_name":"VIRCA NICHOLAS J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2017-03-10T21:16:34.000Z","date":"2017-03-08","kind":"exercise","acquired":false,"shares":15041738,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15041738},"source":{"system":"sec-edgar","filing":"0000899243-17-007152","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007152/doc4.xml","form_type":"4"}},{"id":4391046,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144374,"kind":"person","name":"VIRCA NICHOLAS J","position":1,"cik":"0001284074","reported_name":"VIRCA NICHOLAS J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-03-10T21:16:34.000Z","date":"2017-03-08","kind":"tax_withholding","acquired":false,"shares":6314219,"price":0.34,"value":2146834.46,"ownership":{"direct":true},"balance_after":8727519,"source":{"system":"sec-edgar","filing":"0000899243-17-007152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007152/doc4.xml","form_type":"4"}},{"id":4391045,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":144374,"kind":"person","name":"VIRCA NICHOLAS J","position":1,"cik":"0001284074","reported_name":"VIRCA NICHOLAS J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-03-10T21:16:34.000Z","date":"2017-03-08","kind":"exercise","acquired":true,"shares":15041738,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":15041738,"source":{"system":"sec-edgar","filing":"0000899243-17-007152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007152/doc4.xml","form_type":"4"}},{"id":4391038,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":169549,"kind":"person","name":"Cross Stefan","position":1,"cik":"0001611506","reported_name":"Cross Stefan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-03-10T21:15:34.000Z","date":"2017-03-08","kind":"exercise","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-17-007151","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007151/doc4.xml","form_type":"4"}},{"id":4391037,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":169549,"kind":"person","name":"Cross Stefan","position":1,"cik":"0001611506","reported_name":"Cross Stefan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-03-10T21:15:34.000Z","date":"2017-03-08","kind":"exercise","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-17-007151","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007151/doc4.xml","form_type":"4"}},{"id":4391036,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":169549,"kind":"person","name":"Cross Stefan","position":1,"cik":"0001611506","reported_name":"Cross Stefan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-10T21:15:34.000Z","date":"2017-03-08","kind":"exercise","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":600000,"source":{"system":"sec-edgar","filing":"0000899243-17-007151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007151/doc4.xml","form_type":"4"}},{"id":4391035,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":169549,"kind":"person","name":"Cross Stefan","position":1,"cik":"0001611506","reported_name":"Cross Stefan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-10T21:15:34.000Z","date":"2017-03-08","kind":"exercise","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0000899243-17-007151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007151/doc4.xml","form_type":"4"}},{"id":4391034,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":41246,"kind":"person","name":"Ono Richard Dana","position":1,"cik":"0001595989","reported_name":"Ono Richard Dana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-03-10T21:15:33.000Z","date":"2017-03-08","kind":"exercise","acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs were issued to the reporting person on July 1, 2016, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs were issued to the reporting person on July 1, 2016, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-17-007150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007150/doc4.xml","form_type":"4"}},{"id":4391033,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":41246,"kind":"person","name":"Ono Richard Dana","position":1,"cik":"0001595989","reported_name":"Ono Richard Dana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-03-10T21:15:33.000Z","date":"2017-03-08","kind":"exercise","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-17-007150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007150/doc4.xml","form_type":"4"}},{"id":4391032,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":41246,"kind":"person","name":"Ono Richard Dana","position":1,"cik":"0001595989","reported_name":"Ono Richard Dana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-03-10T21:15:33.000Z","date":"2017-03-08","kind":"exercise","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-17-007150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007150/doc4.xml","form_type":"4"}},{"id":4391031,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":41246,"kind":"person","name":"Ono Richard Dana","position":1,"cik":"0001595989","reported_name":"Ono Richard Dana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-10T21:15:33.000Z","date":"2017-03-08","kind":"tax_withholding","acquired":false,"shares":59400,"price":0.34,"value":20196.0,"ownership":{"direct":true},"balance_after":453000,"source":{"system":"sec-edgar","filing":"0000899243-17-007150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007150/doc4.xml","form_type":"4"}},{"id":4391030,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":41246,"kind":"person","name":"Ono Richard Dana","position":1,"cik":"0001595989","reported_name":"Ono Richard Dana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-10T21:15:33.000Z","date":"2017-03-08","kind":"exercise","acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The RSUs were issued to the reporting person on July 1, 2016, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":512400,"source":{"system":"sec-edgar","filing":"0000899243-17-007150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007150/doc4.xml","form_type":"4"}},{"id":4391029,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":41246,"kind":"person","name":"Ono Richard Dana","position":1,"cik":"0001595989","reported_name":"Ono Richard Dana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-10T21:15:33.000Z","date":"2017-03-08","kind":"tax_withholding","acquired":false,"shares":118800,"price":0.34,"value":40392.0,"ownership":{"direct":true},"balance_after":362400,"source":{"system":"sec-edgar","filing":"0000899243-17-007150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007150/doc4.xml","form_type":"4"}},{"id":4391028,"issuer":{"id":7783,"kind":"organization","name":"Inhibitor Therapeutics, Inc."},"owners":[{"id":41246,"kind":"person","name":"Ono Richard Dana","position":1,"cik":"0001595989","reported_name":"Ono Richard Dana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-10T21:15:33.000Z","date":"2017-03-08","kind":"exercise","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms."}],"balance_after":481200,"source":{"system":"sec-edgar","filing":"0000899243-17-007150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042418/000089924317007150/doc4.xml","form_type":"4"}}],"next_cursor":"2017-03-10T21:15:33.000000Z,4391028"}